Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
31 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
AGY Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'AGY Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the AGY Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of AGY Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of AGY Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of AGY Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the AGY Therapeutics, Inc.'s pipeline products Reasons to buy - Evaluate AGY Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of AGY Therapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the AGY Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of AGY Therapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of AGY Therapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of AGY Therapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 AGY Therapeutics, Inc. Snapshot 5 AGY Therapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 AGY Therapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 AGY Therapeutics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 AGY Therapeutics, Inc. - Pipeline Products Glance 11 AGY Therapeutics, Inc. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 AGY Therapeutics, Inc. - Drug Profiles 13 Small Molecules for Stroke 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Small Molecules to Agonize AGY-208 for Ischemic Stroke 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Small Molecules to Inhibit AGY-221 for Ischemic Stroke 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Monoclonal Antibody to Inhibit AGY-401 for Glioblastoma Multiforme 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Monoclonal Antibody to Inhibit AGY-402 for Glioblastoma Multiforme 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Monoclonal Antibody to Inhibit GPCR for Glioblastoma Multiforme 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Small Molecules to Inhibit AGY-111 for Cognition and Schizophrenia 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Small Molecules to Inhibit AGY-207 for Ischemic Stroke 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Small Molecules to Inhibit Cysteine Protease for Ischemic Stroke 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Small Molecules to Inhibit Protein Kinase for Ischemic Stroke 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecules to Inhibit Tyrosine Phosphatase for Cognition and Schizophrenia 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 AGY Therapeutics, Inc. - Pipeline Analysis 24 AGY Therapeutics, Inc. - Pipeline Products by Target 24 AGY Therapeutics, Inc. - Pipeline Products by Route of Administration 25 AGY Therapeutics, Inc. - Pipeline Products by Molecule Type 26 AGY Therapeutics, Inc. - Pipeline Products by Mechanism of Action 27 AGY Therapeutics, Inc. - Dormant Projects 28 AGY Therapeutics, Inc. - Locations And Subsidiaries 29 Head Office 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 31 Disclaimer 31
List of Tables AGY Therapeutics, Inc., Key Information 5 AGY Therapeutics, Inc., Key Facts 5 AGY Therapeutics, Inc. - Pipeline by Indication, 2014 8 AGY Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9 AGY Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10 AGY Therapeutics, Inc. - Preclinical, 2014 11 AGY Therapeutics, Inc. - Discovery, 2014 12 AGY Therapeutics, Inc. - Pipeline by Target, 2014 24 AGY Therapeutics, Inc. - Pipeline by Route of Administration, 2014 25 AGY Therapeutics, Inc. - Pipeline by Molecule Type, 2014 26 AGY Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 27 AGY Therapeutics, Inc. - Dormant Developmental Projects,2014 28
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.